REFERENCES
1. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10-45.
2. Chan SL, Sun HC, Xu Y, et al. The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment. Lancet. 2025;406:731-78.
3. Yang X, Yang C, Zhang S, et al. Precision treatment in advanced hepatocellular carcinoma. Cancer Cell. 2024;42:180-97.
4. Pinter M, Jain RK, Duda DG. The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review. JAMA Oncol. 2021;7:113-23.
5. Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol. 2021;18:625-44.
6. El-Khoueiry AB, Trojan J, Meyer T, et al. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040. Ann Oncol. 2024;35:381-91.
7. Finn RS, Qin S, Ikeda M, et al.; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894-905.
8. Lee MS, Ryoo BY, Hsu CH, et al.; GO30140 investigators. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21:808-20.
9. Zhu AX, Abbas AR, de Galarreta MR, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28:1599-611.
10. Vesely MD, Zhang T, Chen L. Resistance mechanisms to anti-PD cancer immunotherapy. Annu Rev Immunol. 2022;40:45-74.
11. Zhou KQ, Zhong YC, Song MF, et al. Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution. Hepatology. 2025;82:566-81.
12. Rizzo A, Ricci AD, Brandi G. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opin Investig Drugs. 2021;30:343-50.
13. Cresswell GD, Nichol D, Spiteri I, et al. Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking. Nat Commun. 2020;11:1446.
14. Kwee S, Chen X. Immunotherapy biomarkers for HCC: contemporary challenges and emerging opportunities. Hepatoma Res. 2022;8:32.
16. Yang C, Zhang S, Cheng Z, et al. Multi-region sequencing with spatial information enables accurate heterogeneity estimation and risk stratification in liver cancer. Genome Med. 2022;14:142.
17. Guo W, Sun YF, Shen MN, et al. Circulating tumor cells with stem-like phenotypes for diagnosis, prognosis, and therapeutic response evaluation in hepatocellular carcinoma. Clin Cancer Res. 2018;24:2203-13.
18. Cadamuro M, Fabris L, Zhang X, Strazzabosco M. Tumor microenvironment and immunology of cholangiocarcinoma. Hepatoma Res. 2022;8:11.
19. Khairnar R, Islam MA, Fleishman J, Kumar S. Shedding light on non-alcoholic fatty liver disease: pathogenesis, molecular mechanisms, models, and emerging therapeutics. Life Sci. 2023;312:121185.
20. Llovet JM, Pinyol R, Kelley RK, et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. 2022;3:386-401.
21. Han X, Cai C, Deng W, et al. Landscape of human organoids: Ideal model in clinics and research. Innovation. 2024;5:100620.
22. Thorel L, Perréard M, Florent R, et al. Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology. Exp Mol Med. 2024;56:1531-51.
23. Magré L, Verstegen MMA, Buschow S, van der Laan LJW, Peppelenbosch M, Desai J. Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies. J Immunother Cancer. 2023;11:e006290.
24. Abdolahi S, Ghazvinian Z, Muhammadnejad S, Saleh M, Asadzadeh Aghdaei H, Baghaei K. Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J Transl Med. 2022;20:206.
25. Choi Y, Lee S, Kim K, Kim SH, Chung YJ, Lee C. Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice. Exp Mol Med. 2018;50:1-9.
26. Jenkins RW, Aref AR, Lizotte PH, et al. Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids. Cancer Discov. 2018;8:196-215.
27. Broutier L, Mastrogiovanni G, Verstegen MM, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med. 2017;23:1424-35.
28. Liu S, Liang Z, Zhu L, et al. FXR-mediated antigen-specific CD8+ T cell enhances antitumor immunity in intrahepatic cholangiocarcinoma. J Immunother Cancer. 2025;13:e012259.
29. Song F, Hu B, Liang XL, et al. Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8+ T-cell infiltration in hepatocellular carcinoma. Clin Transl Med. 2024;14:e1738.
30. Hwang S, Jung IJ, Lee KJ, Kim YK, Tak E. Cellular expansion of hepatocellular carcinoma organoids using decellularized liver scaffolds. Clin Transplant Res. 2025;39:366-77.
31. Li Z, Fu C, Chen Y, et al. D-amino acid oxidase suppresses hepatocellular carcinoma via oxidizing D-amino acids. J Transl Med. 2025;23:1359.
32. Xie M, Lin Z, Ji X, et al. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. J Hepatol. 2023;79:109-25.
33. Liu L, Yu L, Li Z, Li W, Huang W. Patient-derived organoid (PDO) platforms to facilitate clinical decision making. J Transl Med. 2021;19:40.
34. Khawar MB, Wang Y, Majeed A, Afzal A, Haneef K, Sun H. Mini-organs with big impact: organoids in liver cancer studies. Oncol Res. 2023;31:677-88.
35. Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020;17:139-52.
36. Parejo-Alonso B, Barneda D, Trabulo SMD, et al. PPARδ orchestrates a prometastatic metabolic response to microenvironmental cues in pancreatic cancer. Cancer Res. 2025;85:3275-91.
37. Airola C, Pallozzi M, Cesari E, et al. Hepatocellular-carcinoma-derived organoids: innovation in cancer research. Cells. 2024;13:1726.
38. Grattarola M, Pons N, Cannet F, et al. Establishment of a mouse hepatocellular carcinoma tumoroid panel recapitulating inter- and intra- heterogeneity for disease modelling and combinatorial drug discovery. Cell Commun Signal. 2025;23:410.
39. Song F, Hu B, Cheng JW, et al. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death Dis. 2020;11:573.
40. Hu B, Li H, Guo W, et al. Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification. Int J Cancer. 2020;146:1606-17.
41. Koga Y, Ochiai A. Systematic review of patient-derived xenograft models for preclinical studies of anti-cancer drugs in solid tumors. Cells. 2019;8:418.
42. Zhao B, Zhou Y, Cheng N, et al. Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications. J Exp Clin Cancer Res. 2025;44:139.
43. Tan M, Ye W, Liu Y, et al. Niclosamide prodrug enhances oral bioavailability and efficacy against hepatocellular carcinoma by targeting vasorin-TGFβ signalling. Br J Pharmacol. 2025;182:5517-35.
44. Zanella ER, Grassi E, Trusolino L. Towards precision oncology with patient-derived xenografts. Nat Rev Clin Oncol. 2022;19:719-32.
45. Xian L, Zhao P, Chen X, et al. Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer. Cell Oncol. 2022;45:1019-36.
46. Yoshida GJ. Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol. 2020;13:4.
47. Zhao Y, Shuen TWH, Toh TB, et al. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Gut. 2018;67:1845-54.
48. Cho K, Ro SW, Seo SH, et al. Genetically engineered mouse models for liver cancer. Cancers. 2019;12:14.
49. Wang T, Liu L, Fang J, et al. Conditional activation of c-MYC in distinct catecholaminergic cells drives development of neuroblastoma or somatostatinoma. Cancer Res. 2025;85:424-41.
50. Spranger S, Gajewski TF. A new paradigm for tumor immune escape: β-catenin-driven immune exclusion. J Immunother Cancer. 2015;3:43.
51. Zhu M, Kim J, Deng Q, et al. Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden. Cancer Cell. 2023;41:1731-48.e8.
53. Moeini A, Haber PK, Sia D. Cell of origin in biliary tract cancers and clinical implications. JHEP Rep. 2021;3:100226.
54. Chen P, Zhang X, Ding R, et al. Patient-derived organoids can guide personalized-therapies for patients with advanced breast cancer. Adv Sci. 2021;8:e2101176.
55. Yáñez-Bartolomé M, Macarulla T, Tian TV. The potential of patient-derived organoids in precision medicine of biliary tract cancer. Cell Rep Med. 2023;4:101294.
56. Zhao JS, Shi S, Qu HY, et al. Glutamine synthetase licenses APC/C-mediated mitotic progression to drive cell growth. Nat Metab. 2022;4:239-53.
57. Hong HK, Yun NH, Jeong YL, et al. Establishment of patient-derived organotypic tumor spheroid models for tumor microenvironment modeling. Cancer Med. 2021;10:5589-98.
58. Aref AR, Campisi M, Ivanova E, et al. 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. Lab Chip. 2018;18:3129-43.
59. Cai J, Song L, Zhang F, et al. Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy in hepatocellular carcinoma. Cancer Commun. 2024;44:1231-60.
60. Ibáñez-Molero S, Veldman J, Simon Nieto J, et al. Tumour-reactive heterotypic CD8 T cell clusters from clinical samples. Nature. 2026;649:467-76.
61. Lee H, Jeong S, Shin EC. Significance of bystander T cell activation in microbial infection. Nat Immunol. 2022;23:13-22.
62. Galvez-Cancino F, Navarrete M, Beattie G, et al. Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies. Immunity. 2025;58:1236-53.e8.
63. Kaptein P, Slingerland N, Metoikidou C, et al. CD8-targeted IL2 unleashes tumor-specific immunity in human cancer tissue by reviving the dysfunctional T-cell pool. Cancer Discov. 2024;14:1226-51.
64. Pelly VS, Moeini A, Roelofsen LM, et al. Anti-inflammatory drugs remodel the tumor immune environment to enhance immune checkpoint blockade efficacy. Cancer Discov. 2021;11:2602-19.
65. Segura-Collar B, Cómitre-Mariano B, López DA, et al. The TRIB2-DNMT1 pathway generates an immune-cold microenvironment in glioblastoma, and its inhibition promotes immunotherapy. Cancer Immunol Res. 2025;13:1022-36.
66. Eguren-Santamaría I, Rodríguez I, Herrero-Martin C, et al. Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism. Oncoimmunology. 2024;13:2373519.
67. McDonald PC, Chafe SC, Brown WS, et al. Regulation of pH by carbonic anhydrase 9 mediates survival of pancreatic cancer cells with activated KRAS in response to hypoxia. Gastroenterology. 2019;157:823-37.
68. Ma H, Zhang VX, Tsui YM, et al. Targeting sterol O-acyltransferase 1 rewires fatty acid metabolism and uncovers immune vulnerability in hepatocellular carcinoma. Hepatology. 2025;Epub ahead of print.
69. Li L, Zhang Y, Zhou Y, et al. Quaternary nanoparticles enable sustained release of bortezomib for hepatocellular carcinoma. Hepatology. 2022;76:1660-72.
70. Dong R, Fei Y, He Y, et al. Lactylation-driven HECTD2 limits the response of hepatocellular carcinoma to lenvatinib. Adv Sci. 2025;12:e2412559.
71. Navarro P, Grazioso TP, Barquín A, et al. Multicenter study correlating molecular characteristics and clinical outcomes of cancer cases with patient-derived organoids. J Exp Clin Cancer Res. 2025;44:182.
72. Tan XP, He Y, Yang J, et al. Blockade of NMT1 enzymatic activity inhibits N-myristoylation of VILIP3 protein and suppresses liver cancer progression. Signal Transduct Target Ther. 2023;8:14.
73. Lee SH, Hu W, Matulay JT, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell. 2018;173:515-28.e17.
74. Fang X, Shu L, Chen T, et al. Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. Mol Cancer. 2024;23:12.
75. Wang Q, Guo F, Jin Y, Ma Y. Applications of human organoids in the personalized treatment for digestive diseases. Signal Transduct Target Ther. 2022;7:336.
76. Saito Y. Establishment of an organoid bank of biliary tract and pancreatic cancers and its application for personalized therapy and future treatment. J Gastroenterol Hepatol. 2019;34:1906-10.
77. Zou Z, Lin Z, Wu C, et al. Micro-engineered organoid-on-a-chip based on mesenchymal stromal cells to predict immunotherapy responses of HCC patients. Adv Sci. 2023;10:e2302640.
78. Fang H, Xu H, Yu J, Cao H, Li L. Human hepatobiliary organoids: recent advances in drug toxicity verification and drug screening. Biomolecules. 2024;14:794.
79. Yang H, Cheng J, Zhuang H, et al. Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer. Cancer Cell. 2024;42:535-51.e8.
80. Ji S, Feng L, Fu Z, et al. Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology. Sci Transl Med. 2023;15:eadg3358.
81. Su SH, Mitani Y, Li T, et al. Lactate suppresses growth of esophageal adenocarcinoma patient-derived organoids through alterations in tumor NADH/NAD+ redox state. Biomolecules. 2024;14:1195.
82. Kong LR, Gupta K, Wu AJ, et al. A glycolytic metabolite bypasses “two-hit” tumor suppression by BRCA2. Cell. 2024;187:2269-87.e16.
83. Zhu Y, Tang S, Yuan Q, et al. Integrated characterization of hepatobiliary tumor organoids provides a potential landscape of pharmacogenomic interactions. Cell Rep Med. 2024;5:101375.
84. Lee H, Kim B, Park J, et al. Cancer stem cells: landscape, challenges and emerging therapeutic innovations. Signal Transduct Target Ther. 2025;10:248.
85. Nikolova MT, He Z, Seimiya M, et al. Fate and state transitions during human blood vessel organoid development. Cell. 2025;188:3329-48.e31.
86. Ooft SN, Weeber F, Dijkstra KK, et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci Transl Med. 2019;11:eaay2574.
87. van Tienderen GS, Groot Koerkamp B, IJzermans JNM, van der Laan LJW, Verstegen MMA. Recreating tumour complexity in a dish: organoid models to study liver cancer cells and their extracellular environment. Cancers. 2019;11:1706.
88. Yamashita T, Wang XW. Cancer stem cells in the development of liver cancer. J Clin Invest. 2013;123:1911-8.
89. Jensen CE, Loaiza-Bonilla A, Bonilla-Reyes PA. Immune checkpoint inhibitors for hepatocellular carcinoma. Hepat Oncol. 2016;3:201-11.
90. Chen K, Liu J, Liu S, et al. Methyltransferase SETD2-mediated methylation of STAT1 is critical for interferon antiviral activity. Cell. 2017;170:492-506.e14.
91. Nanaki S, Barmpalexis P, Iatrou A, Christodoulou E, Kostoglou M, Bikiaris DN. Risperidone controlled release microspheres based on poly(lactic acid)-poly(propylene adipate) novel polymer blends appropriate for long acting injectable formulations. Pharmaceutics. 2018;10:130.
92. Roelofsen LM, Voabil P, de Bruijn M, et al. Protocol for ex vivo culture of patient-derived tumor fragments. STAR Protoc. 2023;4:102282.
93. Jerby-Arnon L, Shah P, Cuoco MS, et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell. 2018;175:984-97.e24.
94. Song F, Wang CG, Wang TL, et al. Enhancement of gemcitabine sensitivity in intrahepatic cholangiocarcinoma through Saikosaponin-a mediated modulation of the p-AKT/BCL-6/ABCA1 axis. Phytomedicine. 2024;133:155944.
95. Wu SY, Zhu YY, Sun JL, et al. Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation. Nat Commun. 2025;16:10039.
96. Ren X, Huang M, Weng W, et al. Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application. Cell Rep Med. 2023;4:101277.
97. Betge J, Rindtorff N, Sauer J, et al. The drug-induced phenotypic landscape of colorectal cancer organoids. Nat Commun. 2022;13:3135.
98. Song F, Wang CG, Mao JZ, et al. PANoptosis-based molecular subtyping and HPAN-index predicts therapeutic response and survival in hepatocellular carcinoma. Front Immunol. 2023;14:1197152.
99. Voabil P, de Bruijn M, Roelofsen LM, et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat Med. 2021;27:1250-61.
100. Papaccio F, García-Mico B, Gimeno-Valiente F, et al. “Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction”. J Exp Clin Cancer Res. 2023;42:8.
101. Anand GM, Megale HC, Murphy SH, et al. Controlling organoid symmetry breaking uncovers an excitable system underlying human axial elongation. Cell. 2023;186:497-512.e23.
102. Nguyen NTB, Gevers S, Kok RNU, et al. Lactate controls cancer stemness and plasticity through epigenetic regulation. Cell Metab. 2025;37:903-19.e10.
103. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603-7.
104. Kapałczyńska M, Kolenda T, Przybyła W, et al. 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. Arch Med Sci. 2018;14:910-9.
105. Guerrero-López P, Martín-Pardillos A, Bonet-Aleta J, et al. 2D versus 3D tumor-on-chip models to study the impact of tumor organization on metabolic patterns in vitro. Sci Rep. 2025;15:19506.
106. DuPage M, Jacks T. Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Curr Opin Immunol. 2013;25:192-9.
107. Ireson CR, Alavijeh MS, Palmer AM, Fowler ER, Jones HJ. The role of mouse tumour models in the discovery and development of anticancer drugs. Br J Cancer. 2019;121:101-8.
108. Hu Y, Sui X, Song F, et al. Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week. Nat Commun. 2021;12:2581.
